Every material Form 8-K ORTHOPEDIATRICS CORP has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OrthoPediatrics filed an October 2026 investor presentation under Regulation FD for executives to use in upcoming meetings with investors and analysts. The deck reports third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, and a narrower net loss of $5.9 million, or $0.25 per diluted share, versus $11.8 million, or $0.50 per share. It also restates full-year 2026 revenue guidance of $270.0 million to $273.0 million.
Q3 2026 revenue was $72.7 million, up from $61.2 million in Q3 2025, a 19% increase.
Q3 2026 net loss was $5.9 million ($0.25 per diluted share), compared with a net loss of $11.8 million ($0.50 per share) in Q3 2025.
FY2026 guidance: revenue of $270.0 million to $273.0 million, adjusted EBITDA of about $25.0 million, and free cash flow breakeven.
Balance sheet as of September 30, 2026 showed cash and short-term investments of $44.9 million and debt of $98.4 million.
OrthoPediatrics reported third-quarter 2026 revenue of $72.7 million, up 19% from a year earlier, and a net loss of $5.9 million, narrower than the $11.8 million loss in the prior-year quarter. The company raised its full-year 2026 revenue guidance to $270.0 million to $273.0 million from $265.0 million to $269.0 million.
Third-quarter revenue was $72.7 million, up 19% from $61.2 million in the third quarter of 2025.
Net loss narrowed to $5.9 million, or $0.25 per share, from $11.8 million, or $0.50 per share, a year earlier.
2026 revenue guidance raised to $270.0 million to $273.0 million from $265.0 million to $269.0 million.
Free cash flow was $1.6 million in the quarter, compared with usage of $3.4 million a year earlier.
OrthoPediatrics furnished an August 2026 investor presentation under Regulation FD, for use by executives in upcoming meetings with investors and analysts. The presentation shows second-quarter 2026 revenue of $70.5 million, up from $61.1 million a year earlier, but a GAAP net loss of $7.2 million, slightly wider than the $7.1 million loss in the prior-year quarter.
Q2 2026 revenue $70.5 million vs. $61.1 million in Q2 2025 (up 15%)
Q2 2026 net loss $7.2 million; GAAP diluted loss per share $0.30, unchanged from Q2 2025
Q2 2026 Adjusted EBITDA $6.8 million vs. $4.1 million; adjusted loss per share $0.26 vs. $0.11
FY2026 revenue guidance range $265.0 million to $269.0 million, 12% to 14% growth
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ORTHOPEDIATRICS CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →